Trastuzumab, pyrotinib and paclitaxel for HER2-positive breast cancer after multi-line targeted therapies

Minerva Med. 2023 Aug;114(4):532-533. doi: 10.23736/S0026-4806.22.08187-3. Epub 2022 May 20.

Authors

Yan Xu¹, Li Ding¹, Chao Li¹, Yongqiang Zhang²

Affiliations

¹ Department of Oncology, National Center of Gerontology, Institute of Geriatric Medicine, Beijing Hospital, Chinese Academy of Medical Sciences, Beijing, China.
² Department of Oncology, National Center of Gerontology, Institute of Geriatric Medicine, Beijing Hospital, Chinese Academy of Medical Sciences, Beijing, China - 18618168070@163.com.

PMID: 35593795
DOI: 10.23736/S0026-4806.22.08187-3

No abstract available

MeSH terms

Acrylamides / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms* / drug therapy
Female
Humans
Paclitaxel / therapeutic use
Receptor, ErbB-2
Trastuzumab / therapeutic use

Substances

Trastuzumab
Paclitaxel
pyrotinib
Acrylamides
Receptor, ErbB-2